# Amphastar Pharmaceuticals Inc. (AMPH)

**Exchange:** NASDAQ  
**Sector:** Healthcare  
**Market cap:** $978M  
**Price:** $20.29 (+0.64%)

> Amphastar Pharmaceuticals Inc. is a biopharmaceutical company specializing in the development, manufacturing, and marketing of generic and proprietary injectable, intranasal, and inhalation products. Its portfolio includes technically challenging medications such as BAQSIMI, the leading prescribed nasal spray glucagon for treating severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation aerosol for mild asthma symptoms; enoxaparin for preventing deep vein thrombosis; naloxone and REXTOVY for opioid overdose reversal; glucagon emergency kits; and Cortrosyn for diagnosing adrenocortical insufficiency. Additional offerings encompass Amphadase hyaluronidase injections, epinephrine for allergic reactions, lidocaine formulations for anesthesia, phytonadione for newborns, morphine for pain management, and lorazepam for procedures. These products serve hospital, urgent care, emergency medical services, and retail pharmacy channels, distributed via group purchasing organizations and wholesalers. Operating from state-of-the-art cGMP-compliant facilities, primarily in the United States with presence in China and France, Amphastar Pharmaceuticals Inc. focuses on one reportable segment: pharmaceutical products, emphasizing complex generics, biologics, biosimilars, and innovative drug delivery systems. Founded in 1996 and headquartered in Rancho Cucamonga, California, it plays a vital role in addressing critical medical needs in the specialty pharmaceutical sector.

## Income Statement (Annual, USD)

| Fiscal Year | Revenue | Gross Profit | Operating Income | Net Income | EPS (dil.) |
| --- | --- | --- | --- | --- | --- |
| 2025 | $720M | $356M | $140M | $98M | — |
| 2024 | $732M | $374M | $205M | $160M | — |
| 2023 | $644M | $351M | $197M | $138M | — |
| 2022 | $499M | $249M | $107M | $91M | — |
| 2021 | $438M | $200M | $70M | $62M | — |
| 2020 | $350M | $143M | $11M | $1M | — |
| 2019 | $322M | $132M | -$39,000 | $49M | — |
| 2018 | $295M | $107M | -$9M | -$6M | — |
| 2017 | $240M | $91M | -$1M | $4M | — |
| 2016 | $255M | $104M | $15M | $10M | — |
| 2015 | $252M | $77M | -$7M | -$3M | — |
| 2014 | $210M | $51M | -$18M | -$11M | — |
| 2013 | $230M | $87M | $17M | $12M | — |
| 2012 | $204M | $90M | $25M | $18M | — |

## Balance Sheet (Annual, USD)

| Fiscal Year | Total Assets | Total Liabilities | Equity | Cash | Long-term Debt |
| --- | --- | --- | --- | --- | --- |
| 2025 | $1.63B | $840M | $789M | $170M | $620M |
| 2024 | $1.58B | $845M | $732M | $152M | $614M |
| 2023 | $1.51B | $873M | $639M | $144M | $603M |
| 2022 | $742M | $213M | $529M | $156M | $77M |
| 2021 | $672M | $226M | $446M | $126M | $78M |
| 2020 | $631M | $183M | $402M | $93M | $46M |
| 2019 | $587M | $159M | $381M | $74M | $46M |
| 2018 | $514M | $149M | $332M | $86M | $49M |
| 2017 | $451M | $117M | $334M | $66M | $46M |
| 2016 | $428M | $98M | $329M | $72M | $36M |
| 2015 | $390M | $95M | $296M | $66M | $40M |
| 2014 | $389M | $108M | $282M | $68M | $43M |
| 2013 | $339M | $87M | $252M | $54M | — |

## Cash Flow (Annual, USD)

| Fiscal Year | Operating Cash Flow | CapEx | Free Cash Flow |
| --- | --- | --- | --- |
| 2025 | $156M | $35M | $121M |
| 2024 | $213M | $41M | $172M |
| 2023 | $184M | $38M | $145M |
| 2022 | $89M | $24M | $65M |
| 2021 | $98M | $27M | $71M |
| 2020 | $57M | $34M | $23M |
| 2019 | $42M | $42M | $207,000 |
| 2018 | $38M | $47M | -$9M |
| 2017 | $39M | $35M | $4M |
| 2016 | $39M | $21M | $17M |
| 2015 | $11M | $16M | -$5M |

Source: [CompaniesByCap](https://companiesbycap.com/company/AMPH)